How to Cultivate Biotech

When Coppell’s ZS Pharma went public last year with a $100 million stock offering, it was hailed as a milestone moment, the first IPO for a Texas biotech startup in more than a decade. In a year’s time, the stock price doubled, boosting the company’s value well above $1 billion. Investors are betting that the FDA will approve the company’s debut drug, ZS-9, designed to battle hyperkalemia and control dangerously high potassium levels. If all goes as planned, the drug will be on the market sometime next year.